DCOY vs DRMA

Decoy Therapeutics Inc. vs Dermata Therapeutics, Inc. — Valuation Comparison 2026

DCOY

Pharmaceutical Preparations
Decoy Therapeutics Inc.
Quality
3.7
out of 10
Value Trap
39
LOW
Price
$8.92
Last close
Models
8/13
Active
VS

DRMA

Pharmaceutical Preparations
Dermata Therapeutics, Inc.
Quality
2.8
out of 10
Value Trap
27
LOW
Price
$1.30
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType DCOY Fair ValueDCOY Upside DRMA Fair ValueDRMA Upside
Bayesian DCF Intrinsic $9.54 +6.9% $1.27 -2.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.72 -87.8% $0.09 -93.3%
Dynamic NAV Asset-Based $20.47 +129.4% $1.26 -2.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for DCOY vs DRMA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DCOY vs DRMA — Which Stock Is More Undervalued?

DCOY scores higher with a 3.7/10 quality rating vs DRMA's 2.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Decoy Therapeutics Inc. (DCOY) and Dermata Therapeutics, Inc. (DRMA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DCOY currently trades at $8.92 with a QOC of 3.7/10, while DRMA trades at $1.30 with a QOC of 2.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).